Rome, Nov 5. (Adnkronos Health) – The Italian Medicines Agency (Aifa) has approved the reimbursement in Italy of selumetinib, an oral and selective Mek inhibitor, for the monotherapy treatment of inoperable, symptomatic plexiform neurofibromas (PN) in adult patients with neurofibromatosis type 1 (Nf1). Alexion, AstraZeneca Rare Disease announced this in a note, stating that Aifa’s approval follows the European Commission’s approval of the drug’s indication extension, based on the results of the Komet study, a large international phase 3 placebo-controlled study that enrolled 145 adult patients from 13 different countries, including North America, South America, Europe, Asia, and Australia, published in ‘The Lancet’. In the primary analysis of the Komet study, selumetinib showed a statistically significant and clinically relevant objective response rate (Orr) compared to placebo. The safety profile was consistent with the already known safety profile and with its established use in pediatric patients.
Nf1 is a rare and progressive genetic disease usually diagnosed in early childhood, but which often progresses into adulthood and can affect all organs – the note explains – Up to 50% of people with Nf1 can develop a type of non-malignant tumor called plexiform neurofibroma which can affect the brain, spinal cord, and nerves. PNs can appear throughout life and grow to large sizes, causing pain, deformity, and muscle weakness, as well as other debilitating symptoms.
“The approval of selumetinib for the treatment of adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas represents an important step forward, extending a therapeutic possibility previously available only to the pediatric population to this patient population as well,” explains Chiara Leoni, head of the Uos Pediatric Rare Diseases and Innovative Therapies at the Agostino Gemelli University Polyclinic Foundation in Rome. “The data confirm the value of selumetinib throughout the entire care pathway in terms of clinical, radiological, and overall quality of life improvement, offering a new therapeutic opportunity both for patients who receive a diagnosis in adulthood and for those facing the transition from pediatric age.”